News By Company | Sirona Biochem Corp. News on T-Net

1 - 10 of 18 Results

Sirona Biochem Signs Agreement with Global Pharmaceutical Company for Clinical Trial of its Novel Skincare Compound TFC-1067/

Vancouver, BC, October 14, 2020--Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) announced that it has signed an agreement with a top 10 global pharmaceutical company to jointly test Sirona's novel skin care, dark spot remover, TFC-1067, in a new clinical study. TFC-1067 will be tested using a new higher concentration (0.4%) and advanced formulation.

Snapshot | Profile | News | Follow

Sirona Biochem Initiates COVID-19 and Infectious Diseases Development Program

Vancouver, BC, April 1, 2020--Sirona Biochem Corp. (TSX-V: SBM) announced that its French subsidiary lab TFChem has initiated an antiviral program to produce potential new antiviral agents to assist in combating COVID-19 and other infectious diseases.

Snapshot | Profile | News | Follow

Sirona Biochem Signs Letter of Intent for Product Commercialization with Top Chinese Pharmaceutical Development Company

Vancouver, BC, March 4, 2020--Sirona Biochem Corp. (TSX-V: SBM) announced that it has signed a Letter of Intent ("LOI") with the Chinese pharmaceutical company, Beijing Huaxi Pharma Co, Ltd., ranked number five in the field of pharmaceutical development in China, to engage in a collaborative effort to bring Sirona's product pipeline to commercial-ready stage for the global market.

Snapshot | Profile | News | Follow

Sirona Biochem Reports 100% Safety in First Toxicology Study for Increased Concentration of TFC-1067/

Vancouver, BC, December 4, 2019--Sirona Biochem Corp. (TSX-V: SBM) announced that the first toxicology test, in preparation for the new clinical study, has been completed with positive results.

Snapshot | Profile | News | Follow

Sirona Biochem Proceeds to First Clinical Tests for Higher Concentrations to Increase Commercial Value of its Skin Lightening Compound TFC-1067

Vancouver, BC, November 19, 2019--Sirona Biochem Corp. TSX-V: SBM) announce that testing of the higher concentration formulation of TFC-1067, first announced in June 2019, will proceed to Human Patch Test, followed by a Human Repeat Insult Patch Test (HRIPT).

Snapshot | Profile | News | Follow

Sirona Biochem Hires Shanghai-based Chemistry Engineer to Select Local Manufacturer for Skin-Lightening Compound TFC-1067

Vancouver, BC, October 24, 2019--Sirona Biochem Corp. (TSX-V: SBM)) announced that it has engaged Mr. Pinqiao Zhao, an applied chemistry engineer from Shanghai, as a consultant to assist Sirona in selecting a manufacturer in China, and to communicate the necessary technical information for production of Sirona's skin lightening compound TFC-1067.

Snapshot | Profile | News | Follow

Sirona Biochem Signs Definitive License & Supply Agreement with Skincare Industry Leader Rodan + Fields

Vancouver, BC, September 24, 2019--Sirona Biochem Corp. (TSX-V: SBM) announced that it has completed a definitive agreement with Rodan + Fields, LLC, a leading skin care brand in the United States[1], for the licensing and commercial sales of novel ingredient TFC-1067 to brighten and even skin tone.

Snapshot | Profile | News | Follow

Sirona Biochem Announces SGLT2 Inhibitor Development Progress

Vancouver, BC, July 12, 2019--Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) has announced that clinical development of Sirona's SGLT2 inhibitor, TFC-039, which is currently well into phase 1 of human trials, is progressing on schedule with no adverse events.

Snapshot | Profile | News | Follow

Sirona Biochem Signs Term Sheet for TFC-1067 with Skincare Industry Leader Rodan + Fields/

Vancouver, BC, June 20, 2019--Sirona Biochem Corp. (TSX-V: SBM) announced that a non-binding term sheet has been signed with Rodan + Fields, LLC (Rodan + Fields) for the commercial sales of novel ingredient TFC-1067.

Snapshot | Profile | News | Follow

Sirona Biochem Reports Approval to Test Higher Concentrations of Skin Lightening Compound TFC-1067

Vancouver, BC, June 13, 2019--Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) announced that it will assess its novel skin lightener, TFC-1067, at a concentration 3 times higher than what was used in the previous clinical trial.

Snapshot | Profile | News | Follow

1 2

Go back in history

Go to top of page

Hiring Today

Latest Tech Jobs

Featured Job: Senior Frontend Engineer

Broadband TV

Skunkworks Research Engineer

DarkVision

Environmental Health and Safety Manager

General Fusion Inc.

Power Electronics Engineer III

Alpha Technologies Ltd

User Experience (UX) Designer

Zscaler Inc.